Your session is about to expire
← Back to Search
Anti-metabolites
pemetrexed for Lymphoma
Phase 2
Waitlist Available
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must have failed prior whole-brain radiotherapy
Must have failed prior radiation therapy > 4 weeks ago
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 6 months of treatment
Awards & highlights
Study Summary
This trial is studying pemetrexed disodium to see how well it works in treating patients with recurrent malignant gliomas, primary CNS lymphoma, or brain metastases.
Eligible Conditions
- Lymphoma
- Brain Tumor
- Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after 6 months of treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 6 months of treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression free survival at 6 months and time to disease progression
Secondary outcome measures
Collect safety data
Compare blood and tissue methylation patterns and correlate with response.
Overall survival
+1 moreSide effects data
From 2022 Phase 3 trial • 1274 Patients • NCT0222089412%
Weight decreased
9%
Diarrhoea
9%
Arthralgia
9%
Alanine aminotransferase increased
9%
Aspartate aminotransferase increased
9%
Haemoptysis
9%
Nasopharyngitis
9%
Bronchitis
9%
Decreased appetite
9%
Hypothyroidism
9%
Constipation
6%
Pruritus
6%
Pneumonia
6%
Cough
6%
Anaemia
6%
Blood alkaline phosphatase increased
6%
Asthenia
6%
Headache
3%
Nausea
3%
Haematemesis
3%
Rash
3%
Pyrexia
3%
Chest pain
3%
Leukopenia
3%
Upper gastrointestinal haemorrhage
3%
Subdural haemorrhage
3%
Lymph gland infection
3%
White blood cell count decreased
3%
Pneumonia bacterial
3%
Tumour associated fever
3%
Dyspnoea
3%
Hyperthyroidism
3%
Myalgia
3%
Hyperglycaemia
3%
Hypertension
3%
Upper respiratory tract infection
3%
Back pain
3%
Malaise
3%
Oedema peripheral
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pembrolizumab Second Course
Pembrolizumab
Chemotherapy (SOC Treatment)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
Pemetrexed 900 mg/m2 every 21 days until disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
FDA approved
Find a Location
Who is running the clinical trial?
Northwestern UniversityLead Sponsor
1,576 Previous Clinical Trials
911,891 Total Patients Enrolled
50 Trials studying Lymphoma
1,135 Patients Enrolled for Lymphoma
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,615 Total Patients Enrolled
1,376 Trials studying Lymphoma
381,553 Patients Enrolled for Lymphoma
Jeffrey J. Raizer, MDStudy ChairRobert H. Lurie Cancer Center
8 Previous Clinical Trials
210 Total Patients Enrolled
2 Trials studying Lymphoma
15 Patients Enrolled for Lymphoma
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger